The iBiopsy® platform is a core business segment focused on developing and commercializing an AI-powered imaging phenotyping system. Research and development activities center on refining algorithms for biomarker identification and patient profiling using CT scan similarity search. The platform utilizes advanced computer vision and machine learning techniques to analyze medical images, providing insights for translational research and clinical decision-making. This segment targets oncology and other therapeutic areas where imaging plays a crucial role. The platform aims to improve patient outcomes by enabling earlier and more accurate diagnoses, personalized treatment strategies, and improved monitoring of disease progression. Market positioning is based on its innovative approach to imaging analysis and its ability to provide actionable insights for clinical trials and research. Future opportunities include expanding the platform's capabilities to cover additional disease areas and integrating with other healthcare technologies. Regulatory and clinical aspects involve obtaining necessary approvals for medical device software and conducting clinical validation studies. Partnerships and collaborations with pharmaceutical companies and research institutions are key to expanding the platform's reach and impact.

This segment provides comprehensive imaging services for clinical trials, encompassing study start-up, image and clinical data management, scientific consulting, independent reviews, image data processing, and site support. Research and development efforts focus on optimizing image analysis workflows, developing new image processing techniques, and ensuring data integrity and security. The segment utilizes advanced imaging technologies and methodologies to support clinical trials in various therapeutic areas, including oncology. The services aim to improve the efficiency and accuracy of clinical trials, leading to faster drug development and improved patient outcomes. Market positioning is based on its expertise in medical imaging and its ability to provide high-quality services to pharmaceutical companies and research organizations. Future opportunities include expanding service offerings, such as incorporating AI-powered image analysis tools, and increasing geographic reach. Regulatory and clinical aspects involve adhering to strict quality standards and regulatory requirements for clinical trial data. Partnerships and collaborations with pharmaceutical companies, CROs, and imaging centers are essential for delivering these services.